I just ran a very detailed analysis through Grok 3 and it ascribes a 92% probability of a 4 letter or better improvement in BCVA. Please note this reflects the probability of success with the SHORE trial as it draws on phase 2 data. It doesn't take into consideration the juicing of the phase 3 study which theoretically should enhance results. Unknowns remain the 52 week duration and efficacy with Eylea.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
60.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $738.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| OPT (ASX) Chart |
Day chart unavailable